Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Opaganib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    RedHill's Opaganib Confirmed as Radioprotective in GI-ARS Study
    RedHill's Opaganib Confirmed as Radioprotective in GI-ARS Study

    10 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/radioprotective-activity-of-redhills-opaganib-for-gi-ars-confirmed-in-new-rncpniaid-study---discussions-ongoing-with-us-government-on-advanced-development-302327260.html

    PR NEWSWIRE
    10 Dec 2024
    Share Share
    RedHill's Opaganib Gets FDA Orphan Drug Status For Childhood Neuroblastoma
    RedHill's Opaganib Gets FDA Orphan Drug Status For Childhood Neuroblastoma

    26 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/redhills-opaganib-granted-orphan-drug-designation-by-the-fda-for-childhood-cancer-neuroblastoma-302230324.html

    PR NEWSWIRE
    26 Aug 2024
    Share Share
    RedHill Announces Positive Obesity and Diabetes Results with Opaganib
    RedHill Announces Positive Obesity and Diabetes Results with Opaganib

    19 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/redhill-announces-positive-obesity-and-diabetes-results-with-opaganib-302225187.html

    PR NEWSWIRE
    19 Aug 2024
    Share Share
    RedHill Patents Opaganib Combo With Checkpoint Inhibitors Through 2040
    RedHill Patents Opaganib Combo With Checkpoint Inhibitors Through 2040

    03 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/redhill-announces-a-new-patent-covering-opaganib-in-combination-with-immune-checkpoint-inhibitors-valid-through-2040-302161731.html

    PR NEWSWIRE
    03 Jun 2024
    Share Share
    RedHill obtains Chinese patent for Opaganib against Ebola
    RedHill obtains Chinese patent for Opaganib against Ebola

    06 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/redhill-announces-new-opaganib-chinese-patent-against-ebola-virus-valid-through-2035-302136648.html

    PR NEWSWIRE
    06 May 2024
    Share Share
    RedHill's Opaganib Selected for Evaluation by BARDA
    RedHill's Opaganib Selected for Evaluation by BARDA

    05 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/redhills-opaganib-selected-for-evaluation-by-barda-and-nih-countermeasures-programs-302079686.html

    PR NEWSWIRE
    05 Mar 2024
    Share Share